evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
Published 3 months ago • 52 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:26
treating richter’s transformation with venetoclax, obinutuzumab and atezolizumab
-
4:48
the evolution of allosct in richter's transformation and its combination with biological agents
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
1:16
the efficacy of car t-cell therapy in richter's transformation
-
1:54
nivolumab ibrutinib for patients with richter’s transformation
-
1:50
novel treatment regimens under investigation for richter's transformation
-
1:26
phase i trial of copanlisib nivolumab in patients with richter’s transformation or transformed fl
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
1:20
analysis of perseus based on high-risk cytogenetic abnormalities
-
7:16
developing a mouse model to elucidate the molecular mechanisms of richter's transformation
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation
-
3:02
euplagia-1: phase i trial of glpg5201, a cd19 car-t product, in r/r cll and richter's transformation
-
1:09
early results from epcore cll-1 trial: subcutaneous epcoritamab in patients with richter’s syndrome
-
1:49
the management of richter's transformation: current approaches and future outlooks
-
2:46
a phase ii trial of pembrolizumab for richter's transformation of cll
-
2:01
the evolution of bcl2 inhibition in cll
-
1:05
risk-factors for richter’s transformation
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
0:58
novel approaches in richter's transformation: car-t and bispecifics
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib